Amplia Therapeutics Limited (INNMF)
USD 0.06
(0.0%)
USD 0.06
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 1.56 Million AUD | -30.29% |
| 2023 | 2.27 Million AUD | 8.35% |
| 2022 | 2.1 Million AUD | 0.0% |
| 2021 | - AUD | 0.0% |
| 2020 | - AUD | -100.0% |
| 2019 | 10.61 Thousand AUD | 0.0% |
| 2018 | 10.61 Thousand AUD | 3.23% |
| 2017 | 10.28 Thousand AUD | 1.26% |
| 2016 | 10.15 Thousand AUD | 0.0% |
| 2015 | - AUD | 0.0% |
| 2014 | - AUD | 0.0% |
| 2013 | - AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 2.16 Million AUD | -4.99% |
| 2024 Q2 | 2.23 Million AUD | 3.59% |
| 2024 Q4 | 1.56 Million AUD | 0.0% |
| 2024 FY | 1.56 Million AUD | -31.38% |
| 2023 Q3 | 2.2 Million AUD | -4.46% |
| 2023 Q1 | 2.23 Million AUD | 6.49% |
| 2023 FY | 2.27 Million AUD | 8.35% |
| 2023 Q2 | 2.3 Million AUD | 3.01% |
| 2023 Q4 | 2.27 Million AUD | 3.39% |
| 2022 Q4 | 2.1 Million AUD | 0.0% |
| 2022 Q2 | - AUD | 0.0% |
| 2022 FY | 2.1 Million AUD | 0.0% |
| 2021 Q4 | - AUD | 0.0% |
| 2021 FY | - AUD | 0.0% |
| 2021 Q2 | - AUD | 0.0% |
| 2020 Q2 | - AUD | 0.0% |
| 2020 Q4 | - AUD | 0.0% |
| 2020 FY | - AUD | -100.0% |
| 2019 FY | 10.61 Thousand AUD | 0.0% |
| 2019 Q4 | 10.61 Thousand AUD | 0.0% |
| 2018 Q4 | - AUD | 0.0% |
| 2018 FY | 10.61 Thousand AUD | 3.23% |
| 2017 Q4 | - AUD | 0.0% |
| 2017 FY | 10.28 Thousand AUD | 1.26% |
| 2016 FY | 10.15 Thousand AUD | 0.0% |
| 2016 Q4 | - AUD | 0.0% |
| 2015 FY | - AUD | 0.0% |
| 2015 Q4 | - AUD | 0.0% |
| 2014 FY | - AUD | 0.0% |
| 2013 FY | - AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 96.21% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 62.112% |
| SQZ Biotechnologies Company | 27.47 Million USD | 94.315% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 96.399% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 94.754% |
| Mesoblast Limited | 118.7 Million USD | 98.684% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -64.691% |
| Genus plc | 233.1 Million USD | 99.33% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 46.706% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -16.235% |
| Marizyme, Inc. | 18.71 Million USD | 91.656% |
| ContraFect Corporation | 2.88 Million USD | 45.792% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -108.229% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -1052.671% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -7.979% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 32.857% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 72.4% |
| MultiCell Technologies, Inc. | 202.58 USD | -770814.7% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 97.283% |
| EV Biologics, Inc. | 1.49 Million USD | -4.48% |
| Q BioMed Inc. | 4.1 Million USD | 62.002% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 95.282% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -147.862% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -27.138% |
| Biomind Labs Inc. | 735.54 Thousand USD | -112.322% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.09% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 87.984% |
| Skye Bioscience, Inc. | 4.61 Million USD | 66.162% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -75.857% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1003.548% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 73.4% |
| IMV Inc. | 28.88 Million USD | 94.593% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -5972.238% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 30.848% |
| GB Sciences, Inc. | 1.75 Million USD | 11.231% |
| Alpha Cognition Inc. | 1.22 Million USD | -27.971% |
| HST Global, Inc. | 98.31 Thousand USD | -1488.42% |
| CSL Limited | 12.18 Billion USD | 99.987% |
| Halberd Corporation | 150 Thousand USD | -941.146% |
| Enzolytics Inc. | 996.33 Thousand USD | -56.746% |
| Resverlogix Corp. | 6.49 Million USD | 75.94% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -227.062% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -511.02% |
| argenx SE | 20 Million USD | 92.191% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 96.572% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 42.344% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -15173.535% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.626% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -678.462% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 34.867% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -581.108% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 97.691% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 48.393% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -334.161% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 92.317% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -950.573% |
| BioStem Technologies, Inc. | 4.71 Million USD | 66.852% |
| ONE Bio Corp. | 19.71 Million USD | 92.079% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -524.233% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -527.902% |
| Agentix Corp. | 50 Thousand USD | -3023.438% |
| LadRx Corporation | 33.6 Thousand USD | -4547.143% |
| Cell Source, Inc. | 9.25 Million USD | 83.124% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -106.521% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -106.521% |
| NovAccess Global Inc. | 2.19 Million USD | 29.009% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 77.919% |
| Itoco Inc. | 228.37 Thousand USD | -583.834% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -640.239% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 68.659% |
| Kadimastem Ltd | 891.22 Thousand USD | -75.233% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -288.633% |
| CytoDyn Inc. | 30.07 Million USD | 94.807% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -222.48% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -343.863% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 80.029% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -1174.873% |
| Rebus Holdings, Inc. | 310 Thousand USD | -403.78% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 67.02% |
| International Stem Cell Corporation | 4.17 Million USD | 62.62% |
| Bioxytran, Inc. | 1.92 Million USD | 18.872% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -2402.234% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 28.391% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 81.22% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 81.809% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -0.401% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -482.731% |
| Neutra Corp. | 54.15 Thousand USD | -2783.741% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 14.66% |
| PureTech Health plc | 25.51 Million USD | 93.878% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -27.568% |
| IXICO plc | 472.02 Thousand USD | -230.857% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 89.925% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 97.492% |
| CSL Limited | 12.18 Billion USD | 99.987% |
| Cellectis S.A. | 92.77 Million USD | 98.317% |